Cholecystokinin-2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - results of the lumed phase 0a study

Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, Schibli R, Geistlich S, Schumann A, Rau T, Glatz K, Behe M, Christ ER & Wild D
Choose the citation style.
Rottenburger, C., Nicolas, G. P., McDougall, L., Kaul, F., Cachovan, M., Vija, A. H., … Wild, D. (2020). Cholecystokinin-2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - results of the lumed phase 0a study. Journal of Nuclear Medicine, 61(4), 520-526. https://doi.org/10.2967/jnumed.119.233031